9EP Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Late‑stage Pipeline ProgressMoving zelicapavir into a registrational Phase 2b/3 program represents a durable de‑risking of Enanta's lead antiviral franchise. Late‑stage trials, prior positive Phase 2 signal and Fast Track status position the company to capture structural RSV market opportunity and enable definitive commercialization or high‑value partnering outcomes if results validate efficacy and hospitalization reductions.
Partner‑focused Business ModelEnanta's revenue model centered on discovery collaborations, milestone payments and royalties provides persistent non‑commercial cash flow optionality and lowers capital intensity versus building a broad in‑house commercial organization. Durable partner economics can fund R&D, transfer commercialization risk to larger pharma, and monetize discovery capabilities over multiple programs.
Improving Leverage ProfileMaterial improvement in leverage reduces near‑term solvency risk and increases financial flexibility for a loss‑making biotech. A lower debt burden and larger equity cushion enhance the company's ability to fund late‑stage trials and absorb development setbacks while preserving optionality for strategic licensing or selective capital raises without immediate refinancing stress.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means Enanta remains reliant on external capital or partner funding to advance programs. Even with improved burn, continued outflows create ongoing dilution or financing risk, constrain strategic flexibility, and force prioritization of programs, which can delay or limit investments needed to commercialize late‑stage assets.
Ongoing UnprofitabilityDespite a strong revenue rebound, deeply negative operating margins and a large net loss indicate the core business has not reached sustainable profitability. This structural earnings weakness increases dependency on milestone/royalty timing and exposes the company to adverse surprises if partnered revenues or trial outcomes falter, limiting internal reinvestment capacity.
Adverse Patent RulingA federal appeals ruling invalidating a key patent weakens Enanta's IP protection and reduces leverage in monetizing antiviral discoveries. Loss of enforceable claims is a durable structural headwind: it can limit damages or licensing outcomes, reduce deterrence against competitors, and complicate future litigation strategy that the company might rely on to capture value from proprietary discoveries.
Enanta Pharmaceuticals News
9EP FAQ
What was Enanta Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Enanta Pharmaceuticals’s market cap?
Enanta Pharmaceuticals’s market cap is CHF304.20M.
When is Enanta Pharmaceuticals’s upcoming earnings report date?
Enanta Pharmaceuticals’s upcoming earnings report date is Aug 10, 2026 which is in 15 days.
How were Enanta Pharmaceuticals’s earnings last quarter?
Enanta Pharmaceuticals released its earnings results on May 11, 2026. The company reported -$0.367 earnings per share for the quarter, beating the consensus estimate of -$0.398 by $0.03.
Is Enanta Pharmaceuticals overvalued?
According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued.
Does Enanta Pharmaceuticals pay dividends?
Enanta Pharmaceuticals does not currently pay dividends.
What is Enanta Pharmaceuticals’s EPS estimate?
Enanta Pharmaceuticals’s EPS estimate is -0.42.
How many shares outstanding does Enanta Pharmaceuticals have?
Currently, no data Available
What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?
Enanta Pharmaceuticals reported an EPS of -$0.367 in its last earnings report, beating expectations of -$0.398. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Enanta Pharmaceuticals?
Currently, no hedge funds are holding shares in CH:9EP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enanta Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
174.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.57%
Trailing 12-Months
Company Description
Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
9EP Stock 12 Month Forecast
Average Price Target
$16.26
Abeona Therapeutics
―
Tectonic Therapeutic
―
Allogene Therapeutics
―
Jade Biosciences
―
Neumora Therapeutics, Inc.
―